In vitro selection and characterization of VX-478 resistant HIV-1 variants

Advances in Experimental Medicine and Biology

Volumn 436, Issue , 1998, Pages 75-83

  Pazhanisamy, S ^a   Partaledis, Judith A ^a   Rao, B G ^a   Livingston, David J ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; GAG PROTEIN; INDINAVIR; MUTANT PROTEIN; POL PROTEIN; PROTEINASE; SAQUINAVIR; UNCLASSIFIED DRUG; VB 11328;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CONFERENCE PAPER; ENZYME SPECIFICITY; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR MODEL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROCESSING; VIRION; VIRUS RESISTANCE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0031920096     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-5373-1_10     Document Type: Conference Paper

References (16)

1. Meek, T. D. (1992) J. Enz. Inhib. 6, 65-98.
2. Wlodawer, A., and Erickson, J. W. (1993) Annu. Rev. Biochem. 62, 543-585.
3. Darke, P. L., and Huff, J. R. (1994) Adv. Pharmacol. 25, 399-454.
4. Pillay, D., Getman, M. B. D., and Richman, D. D. (1995) Rev. Med. Virology 5, 23-33.
5. De Clercq, E. (1995) J. Med. Chem. 38, 2491-2517.
6. XI International Conference on AIDS, Vancouver, Canada, 1996. Abstract # Mo. B. 1137 and # Mo. B. 170.
7. Studenberg, S. D., Dhal, R. A, and Wooley, J. L. on " Pharmacokinetics, Excretion, and Mass Balance Studies in Dogs with 141W94 (VX-478), an HIV-1 Protease Inhibitor." Presented at the 7th International Society for the Study of Xenobiotics, San Diego, CA, 1996. Abstract # 327.
8. Painter, G. R., Ching, S., Reynolds, D., St.Clair, M., Sadler, B. M., Elkins, M., Blum, R., Dornsife, R., Livingston, D., Partaledis, J. A., Pazhanisamy, S., Tung, R. and Tisdale, M. (1996) Drugs of the Future 21, 347-350.
9. St. Clair, M.H., Millard, J., Tisdale, M., Parry, N., Sadler, B.M., Blum, M. R., and Painter, G. on "Invitro antiviral activity of 141W94 (VX-478) in combination with other antiviral agents." Presented at the Consensus Symposium on Combined Antiviral Therapy, Lisbon, Portugal, July 26; 1995.
10. 3" Presented at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, La. Abstract # LB7a.
11. Schechter, I., and Berger, A. (1967) Biochem. Biophys. Res. Commun. 27, 157-162.
12. Partaledis, J. A., Yamaguchi, K., Tisdale, M., Blair, E. E., Falcione, C., Maschera, B., Myers, R. E., Pazhanisamy, S., Futer, O., Cullinan, A. B., Stuver, C. M., Byrn, R. A., and Livingston, D. J. (1995) J. Virology. 69, 5228-5235.
13. Pazhanisamy, S., Stuver, C. M., Cullinan, A. B., Margolin, N., Rao, B. G. and Livingston, D. J. (1996) J. Biological Chem. 271, 17979-17985.
14. Collins, J. R., Burt, S. K., and Erickson, J. W. (1995) Nature Struct. Biol. 2, 334-338.
15. Debouk, C. (1991) Adv. Exp. Med. Biol. 306, 407-415.
16. Gulnik, S. V., Suvorov, L. I., Liu, B., Yu, B., Anderson, B., Mitsuya, H., and Erickson, J. W. (1995) Biochem. 34, 9282-9287.